Glenmark Pharmaceuticals on Wednesday launched ‘affordable’ gliptin for treatment of Type-2 Diabetes mellitus.
Glenmark Pharmaceuticals on Wednesday launched ‘affordable’ gliptin for treatment of Type-2 Diabetes mellitus. The company introduced Teneligliptin, a new third-generation oral anti-diabetic agent, under two brands —Ziten and Zita Plus.
It has priced the drug at Rs 19.90 a tablet and claims it is 55% cheaper than other drugs in the market. Most gliptins are priced at Rs 45 a tablet. This means, a patient can save up to Rs 9,000 a year, said the company. Currently, many other firms such as USV and Sun Pharma sell gliptins. However, Glenmark said it is the first Indian company to introduce the molecule after clinical trials and approval from the Drug Controller General of India (DCGI) for exclusive sale in India.